Clinical trial
Study Evaluating Inhibitor Specificity in Hemophilia A
NCT00151385 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Withdrawn
Key facts
| NCT number | NCT00151385 |
|---|---|
| Title | Study Evaluating Inhibitor Specificity in Hemophilia A |
| Official title | A Multicenter Study to Describe the Immunogenic Epitope(s) of Factor VIII in Previously Treated Patients With Congenital Hemophilia A Who Develop De Novo Factor VIII Inhibitors While Receiving Factor VIII Infusion Therapy. |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Withdrawn |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Procedure |
| Interventions | single blood draw |
| Enrollment | 0 |
| Start date | Nov 1, 2005 |
| Completion | Oct 1, 2007 |
| First posted | Sep 8, 2005 |
| Last update posted | Jun 28, 2012 |
| Countries | Belgium, France, Germany, Italy, Spain, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: